• February 14, 2017 at 3:39 pm #1219
    admin
    Keymaster

    Regen BioPharma, Inc. (RGBP) focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrows; HemaXellerate II, a donor endothelial cell based therapeutic product; dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer; and NR2F6, a nuclear receptor cell line. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.

    [stock-quotes-list symbols=”RGBP” stockExchange=”OTCBB” width=”100%” height=”380″ motif=”financial” palette=”financial-light” includeChart=”true”]

    • This topic was modified 8 months, 3 weeks ago by admin.
    • This topic was modified 7 months, 2 weeks ago by admin.
    • This topic was modified 7 months, 2 weeks ago by admin.
    • This topic was modified 7 months, 2 weeks ago by tomasp.
    • This topic was modified 7 months, 2 weeks ago by tomasp.
    • This topic was modified 7 months, 2 weeks ago by tomasp.
    • This topic was modified 7 months, 2 weeks ago by tomasp.
    • This topic was modified 7 months, 2 weeks ago by tomasp.
    • This topic was modified 7 months, 2 weeks ago by tomasp.

You must be logged in to reply to this topic.